Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03855514
Other study ID # 18-DFU-005-NUS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 8, 2019
Est. completion date December 30, 2021

Study information

Verified date May 2021
Source Organogenesis
Contact Galen Hale
Phone (205) 541-9682
Email GHale@organo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective, multi-center, randomized, controlled clinical study compares NuShield® plus SOC to SOC alone in subjects with chronic DFUs. NuShield® will be used along with standard of care on diabetic foot ulcers of greater than 6 weeks which have not adequately responded to conventional ulcer therapy.


Description:

Two hundred (200) subjects with a chronic DFU ranging in size from 0.5cm2 and 25 cm2 will be randomized 1:1 to either NuShield® and SOC or SOC alone following the 14 day screening period. Following screening and randomization, subjects shall be seen weekly for up to 24 weeks. For subjects that heal prior to week 24, a healing confirmation visit shall occur two weeks later to confirm maintenance of complete wound closure. Subjects that are randomized into the SOC group whose DFU has not healed by week 12 may be crossed over to receive NuShield® and followed for an additional 12-14 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 30, 2021
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. At least 18 years old and maximum of 85 years old. 2. Subjects with a diabetic foot ulcer that is either superficial, e.g. not involving tendon, capsule, or bone; or wounds that penetrate into tendon, capsule, bone and/or joint. 3. Subjects, with the presence of Diabetes, must have a Glycosylated hemoglobin (HbA1c) = 12% within 4 weeks prior to randomization 4. Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit with no upper limit in duration of non-healing. 5. Subject has adequate circulation to the foot as documented by either: Skin perfusion pressure (SPP) measurement of = 45 mmHg, Toe-brachial index (TBI) = 0.6/ Toe pressure greater than 40, Ankle-brachial index (ABI) between 0.60 and = 1.3 6. Index ulcer is a minimum of 0.5 cm2 and a maximum of 25cm2 at randomization, prior to first study treatment. 7. The index ulcer has been offloaded for 14 days prior to randomization. 8. Index ulcer has not reduced in area > 20% from Day -14 to Day 0, prior to randomization. 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen. 10. Subject, or their Legally Authorized Representative (LAR), has read, understood, and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken. Exclusion Criteria: 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes. 2. Treatment with HBO wound dressings that include growth factors, bioengineered tissues, or skin substitutes within 30 days of randomization. 3. History of bone cancer or metastatic disease of the affected limb or chemotherapy within the 12 months prior to randomization. 4. Subjects with a history of more than two weeks treatment with immunosuppressants (including prednisone 10 mg daily or an equivalent does of other oral steroids cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study. 5. Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding the first Screening Visit. 6. History of radiation at the ulcer site. 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies within 30 days prior to randomization. 8. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment. 9. Active infection at the index ulcer at the time of Randomization. 10. Acute osteomyelitis or bone infection of the affected foot, where subject has received less than 4 weeks of systemic antibiotics at the time of Screening and less than 6 weeks prior to Randomization (systemic antibiotic regimen must be completed at the time of Randomization). 11. Subject's with suspected infection who have received less than 2 weeks of systemic antibiotics, or have not had surgical resection of clinically diagnosed osteomyelitis 12. Subjects with suspected osteomyelitis who have not had an X-ray, CT scan or MRI within 14 days prior to Randomization. 13. Subject is unwilling or unable to comply with the study requirement for offloading the index wound 14. Subject is pregnant or breast feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
NuShield
NuShield® is a dehydrated placental allograft.

Locations

Country Name City State
United States Family Foot & Ankle Specialists Bridgeport Connecticut
United States ILD Research Center Carlsbad California
United States Limb Preservation Platform Fresno California
United States University of Southern California Los Angeles California
United States Futuro Clinical Trials McAllen Texas
United States Doctors Research Network Miami Florida
United States NYU Winthrop Hospital New York New York
United States Stanford University Redwood City California
United States Extremity Healthcare Roswell Georgia

Sponsors (1)

Lead Sponsor Collaborator
Organogenesis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of time that a wound achieves complete wound closure (CWC) Duration (number of days) to achieve CWC from baseline to week 12 assessed between both groups 12 weeks
Secondary Greater than 40% wound closure at week 4 from baseline Proportion of subjects achieving = 40% wound closure at Week 4 from baseline 4 weeks
Secondary Change in wound area Mean percent change from baseline in wound area at Week 12 12 weeks
Secondary Incidence of prescribed pain and/or neuropathic medications Cumulative amount of pain and neuropathic medications taken between baseline and Week 12 assessed between both groups. 12 weeks
Secondary Reduction in subject reported pain at week 12 from baseline assessed between both groups via the Numeric Pain Rating Scale (NPRS) Mean percent change at week 12 in subject reported pain, assessed via the NPRS pain scale where 0 = no pain and 10 = worst pain imaginable, on a scale of 0 to 10. 12 weeks
Secondary Utilization of healthcare resources assessment Utilization of healthcare resources through Week 12 12 weeks
Secondary Improvement in subject reported quality of life at week 12 from baseline assessed via the Wound-QoL (Questionnaire on quality of life with chronic wounds). Mean percent change at week 12 from baseline in subject reported quality of life scores between both groups. The 17 item Wound-QoL tool measures the disease-specific, health-related quality of life of patients with chronic wounds. A global score is computed by averaging all 17 items where subjects answer each question on a scale of 0 to 4, where 0=not at all and 4=very much. 12 weeks
Secondary Time to complete wound closure (CWC) by or on 24 weeks Length of time wounds achieve CWC at week 24 from baseline 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A